Table 2 Population demographics and characteristics at baseline.
From: Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort
Characteristic | Survivors (n = 970) | Non-survivors (n = 30) | P-value |
|---|---|---|---|
Age (yr) | 63 ± 7 | 68 ± 6 | P < 0.0001 |
Female sex | 351 (36) | 11 (37) | P = 0.14 |
Body-mass-index | 27 ± 5.8 | 28 ± 7.4 | P = 0.80 |
Smoking status | |||
Current smoker | 364 (38) | 3 (10) | P = 0.002 |
Smoking history (pack-yr) | 47 ± 25 | 56 ± 42 | P = 0.92 |
Clinical variables | |||
FEV1 (L) | 1.42 ± 0.5 | 1.35 ± 0.5 | P = 0.41 |
FEV1 (% predicted) | 46 ± 15 | 46 ± 13 | P = 0.99 |
GOLD stage | P = 0.708 | ||
II | 480 (50) | 14 (47) | |
III | 390 (40) | 14 (47) | |
IV | 98 (10) | 2 (6.7) | |
Number of previous exacerbations | P = 0.0170 | ||
0 | 432 (45) | 10 (33) | |
1 | 244 (25) | 12 (40) | |
2 | 144 (15) | 0 (0) | |
>2 | 148 (15) | 8 (27) | |
mMRC dyspnea score | 1 (1;2) | 2 (1;3) | P = 0.023 |
%LLA | 16 ± 11 | 17 ± 11 | P = 0.45 |
BODE index | 3 (1;4) | 3.5 (2;5) | P = 0.063 |
Treatments | |||
Inhaled corticosteroids | 139 (14) | 3 (10) | P = 0.048 |
Systemic corticosteroids | 8 (0.8) | 0 | P = 0.77 |
Statins | 237 (24) | 6 (20) | P = 0.37 |
Biomarkers | |||
ELP-3 | 26.8 ± 15.7 | 41.7 ± 32.7 | P = 0.020 |
EL-CG | 1.7 ± 1.3 | 2.6 ± 2.6 | P = 0.066 |
EL-NE | 10.1 ± 9.7 | 11.8 ± 8.8 | P = 0.16 |
ELM7 | 2.8 ± 0.9 | 3.0 ± 1.0 | P = 0.16 |
ELM12 | 4.5 ± 5.5 | 5.1 ± 5.4 | P = 0.22 |
